The ARDURA Trial on EGFR Mutated Non-Small Cell Lung Cancer

The ADORA phase three trial enrolled patients with stage 1B to 3A non-small cell lung cancer that harbored a mutation in EGFR. The disease free survival endpoint had already been previously reported and was statistically significantly in favor of the awesome mertinib arm prolonging disease free survival. This is now the first study to show that adjuvant therapy with an EGFR tyrosine kinase inhibitor can lead to a statistically significant overall survival benefit, Dr. Ng says.